{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:21:19Z","timestamp":1780082479946,"version":"3.54.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s15010-024-02371-1","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T06:02:11Z","timestamp":1724479331000},"page":"2183-2193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ceftazidime-avibactam versus other antimicrobial agents for treatment of Multidrug-resistant Pseudomonas aeruginosa: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"52","author":[{"given":"Chhavi","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan Shin-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monalisa","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipta","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Sheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"key":"2371_CR1","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/antibiotics9040196","volume":"9","author":"S Morris","year":"2020","unstructured":"Morris S, Trends Cerceo E. Epidemiology, and management of multi-drug resistant gram-negative bacterial infections in the hospitalized setting. Antibiotics (Basel). 2020;9:196.","journal-title":"Antibiotics (Basel)"},{"key":"2371_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13756-018-0370-9","volume":"7","author":"G Raman","year":"2018","unstructured":"Raman G, Avendano EE, Chan J, Merchant S, Puzniak L. Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2018;7:79.","journal-title":"Antimicrob Resist Infect Control"},{"key":"2371_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/2047-2994-3-32","volume":"3","author":"D Nathwani","year":"2014","unstructured":"Nathwani D, Raman G, Sulham K, Gavaghan M, Menon V. Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2014;3:32.","journal-title":"Antimicrob Resist Infect Control"},{"key":"2371_CR4","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","volume":"10","author":"A Soriano","year":"2021","unstructured":"Soriano A, Carmeli Y, Omrani AS, Moore LSP, Tawadrous M, Irani P. Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review. Infect Dis Ther. 2021;10:1989\u20132034.","journal-title":"Infect Dis Ther"},{"key":"2371_CR5","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/antibiotics10091126","volume":"10","author":"GL Daikos","year":"2021","unstructured":"Daikos GL, da Cunha CA, Rossolini GM, Stone GG, Baillon-Plot N, Tawadrous M, et al. Review of ceftazidime-avibactam for the treatment of infections caused by Pseudomonas aeruginosa. Antibiotics (Basel). 2021;10:1126.","journal-title":"Antibiotics (Basel)"},{"key":"2371_CR6","doi-asserted-by":"publisher","first-page":"1137811","DOI":"10.3389\/fmicb.2023.1137811","volume":"14","author":"Q Yuan","year":"2023","unstructured":"Yuan Q, Guo L, Li B, Zhang S, Feng H, Zhang Y, et al. Risk factors and outcomes of inpatients with carbapenem-resistant Pseudomonas aeruginosa bloodstream infections in China: a 9-year trend and multicenter cohort study. Front Microbiol. 2023;14:1137811.","journal-title":"Front Microbiol"},{"key":"2371_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2016.22","volume":"5","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Chen XL, Huang AW, Liu SL, Liu WJ, Zhang N, et al. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies. Emerg Microbes Infect. 2016;5: e27.","journal-title":"Emerg Microbes Infect"},{"key":"2371_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious diseases society of america 2022 guidance on the treatment of extended-spectrum beta-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75:187\u2013212.","journal-title":"Clin Infect Dis"},{"key":"2371_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, Tangden T, Bitterman R, Bonomo RA, et al. European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28:521\u201347.","journal-title":"Clin Microbiol Infect"},{"key":"2371_CR10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jmii.2022.02.001","volume":"55","author":"CL Sy","year":"2022","unstructured":"Sy CL, Chen PY, Cheng CW, Huang LJ, Wang CH, Chang TH, et al. Recommendations and guidelines for the treatment of infections due to multidrug-resistant organisms. J Microbiol Immunol Infect. 2022;55:359\u201386.","journal-title":"J Microbiol Immunol Infect"},{"key":"2371_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs. 2018;78:675\u201392.","journal-title":"Drugs"},{"key":"2371_CR12","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/jac\/dks523","volume":"68","author":"C Lucasti","year":"2013","unstructured":"Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind. Phase II trial J Antimicrob Chemother. 2013;68:1183\u201392.","journal-title":"Phase II trial J Antimicrob Chemother"},{"key":"2371_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomized, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16:661\u201373.","journal-title":"Lancet Infect Dis"},{"key":"2371_CR14","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","volume":"62","author":"JE Mazuski","year":"2016","unstructured":"Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, et al. Efficacy and Safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62:1380\u20139.","journal-title":"Clin Infect Dis"},{"key":"2371_CR15","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","volume":"63","author":"FM Wagenlehner","year":"2016","unstructured":"Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016;63:754\u201362.","journal-title":"Clin Infect Dis"},{"key":"2371_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","volume":"49","author":"X Qin","year":"2017","unstructured":"Qin X, Tran BG, Kim MJ, Wang L, Nguyen DA, Chen Q, et al. A randomized, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalized adults in Asia. Int J Antimicrob Agents. 2017;49:579\u201388.","journal-title":"Int J Antimicrob Agents"},{"key":"2371_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","volume":"18","author":"A Torres","year":"2018","unstructured":"Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomized, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285\u201395.","journal-title":"Lancet Infect Dis"},{"key":"2371_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"2371_CR19","doi-asserted-by":"crossref","unstructured":"Chi KY, Li MY, Chen C, Kang E; Cochrane Taiwan. Ten circumstances and solutions for finding the sample mean and standard deviation for meta-analysis. Syst Rev. 2023;12(1):62.","DOI":"10.1186\/s13643-023-02217-1"},{"key":"2371_CR20","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00405-23","author":"TA Almangour","year":"2023","unstructured":"Almangour TA, Ghonem L, Alassiri D, Aljurbua A, Al Musawa M, Alharbi A, et al. Ceftolozane-tazobactam versus ceftazidime-avibactam for the treatment of infections caused by multidrug-resistant pseudomonas aeruginosa: a multicenter cohort study. Antimicrob Agents Chemother. 2023. https:\/\/doi.org\/10.1128\/aac.00405-23.","journal-title":"Antimicrob Agents Chemother"},{"key":"2371_CR21","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2147\/IDR.S350976","volume":"15","author":"J Chen","year":"2022","unstructured":"Chen J, Liang Q, Chen X, Wu J, Wu Y, Teng G, et al. Ceftazidime-avibactam versus polymyxin b in the challenge of carbapenem-resistant Pseudomonas aeruginosa Infection. Infect Drug Resist. 2022;15:655\u201367.","journal-title":"Infect Drug Resist"},{"key":"2371_CR22","doi-asserted-by":"crossref","unstructured":". Golia A, Guo Y, Chang M H, McSweeney TD, Lee P J et al. 1729. Real-world Experience with Ceftazidime-avibactam Compared with Ceftolozane-tazobactam on Clinical Outcomes in\u00a0Pseudomonas aeruginosa\u00a0Infections,\u00a0Open Forum Infectious Diseases, Volume 9, Issue Supplement_2, December 2022, ofac492.135.","DOI":"10.1093\/ofid\/ofac492.1359"},{"key":"2371_CR23","doi-asserted-by":"crossref","unstructured":". Lawandi A, Mishuk AU, Yek C, Yu A, Li X , Strich RJ et al. 1649. Ceftolozane-Tazobactam or Ceftazidime-Avibactam Versus Best Available Therapy in the Treatment of Difficult-to-Treat Pseudomonas aeruginosa Infections: A Retrospective Comparative Effectiveness Analysis of 195 U.S. Hospitals, 2016\u20132020,\u00a0Open Forum Infectious Diseases, Volume 9, Issue Supplement_2, December 2022, ofac492.115,","DOI":"10.1093\/ofid\/ofac492.115"},{"key":"2371_CR24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1086\/338782","volume":"34","author":"M David","year":"2002","unstructured":"David M. Livermore, multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34:634\u201340.","journal-title":"Clin Infect Dis"},{"key":"2371_CR25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40121-022-00591-2","volume":"11","author":"AJ Kunz Coyne","year":"2022","unstructured":"Kunz Coyne AJ, El Ghali A, Holger D, Rebold N, Rybak MJ. Therapeutic strategies for emerging multidrug-resistant pseudomonas aeruginosa. Infect Dis Ther. 2022;11:661\u201382.","journal-title":"Infect Dis Ther"},{"key":"2371_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cid\/ciw243","volume":"63","author":"D van Duin","year":"2016","unstructured":"van Duin D, Bonomo RA. Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-Lactam\/\u03b2-Lactamase inhibitor combinations. Clin Infect Dis. 2016;63:234\u201341.","journal-title":"Clin Infect Dis"},{"key":"2371_CR27","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1128\/AAC.00860-06","volume":"51","author":"S Takeda","year":"2007","unstructured":"Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2007;51:826\u201330.","journal-title":"Antimicrob Agents Chemother"},{"key":"2371_CR28","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1093\/jac\/dkw239","volume":"71","author":"M Falcone","year":"2016","unstructured":"Falcone M, Paterson D. Spotlight on ceftazidime\/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother. 2016;71:2713\u201322.","journal-title":"J Antimicrob Chemother"},{"key":"2371_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.780940","volume":"12","author":"J Fang","year":"2021","unstructured":"Fang J, Li H, Zhang M, et al. Efficacy of ceftazidime-avibactam versus polymyxin b and risk factors affecting clinical outcomes in patients with carbapenem-resistant Klebsiella pneumoniae Infections a retrospective study. Front Pharmacol. 2021;12: 780940.","journal-title":"Front Pharmacol"},{"key":"2371_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/17425255.2018.1434142","volume":"14","author":"M Falcone","year":"2018","unstructured":"Falcone M, Viale P, Tiseo G, Pai M. Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia. Expert Opin Drug Metab Toxicol. 2018;14:331\u201340.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2371_CR31","doi-asserted-by":"publisher","first-page":"106090","DOI":"10.1016\/j.micpath.2023.106090","volume":"179","author":"T Karampatakis","year":"2023","unstructured":"Karampatakis T, Tsergouli K, Lowrie K. Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis. Microb Pathog. 2023;179:106090.","journal-title":"Microb Pathog"},{"key":"2371_CR32","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1093\/jac\/dky204","volume":"73","author":"GG Stone","year":"2018","unstructured":"Stone GG, Newell P, Gasink LB, Broadhurst H, Wardman A, Yates K, et al. Clinical activity of ceftazidime\/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime\/avibactam Phase III clinical trial programme. J Antimicrob Chemother. 2018;73:2519\u201323.","journal-title":"J Antimicrob Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02371-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02371-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02371-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T19:06:21Z","timestamp":1733425581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02371-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2371"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02371-1","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,24]]},"assertion":[{"value":"2 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict on interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}